Recently, a study focusing on non-Hodgkin’s lymphoma demonstrated that CD47 (a tumor stemness-associated gene) is highly upregulated in the tumor cells of some patients, and is resistant to monoclonal antibody (rituximab) therapy. This evidence concerns the gene CD47 and neoplasm.